Show simple item record

dc.contributor.authorChllamma, M
dc.contributor.authorCook, Natalie
dc.contributor.authorDhani, N
dc.contributor.authorGiby, K
dc.contributor.authorDodd, A
dc.contributor.authorWang, L
dc.contributor.authorHedley, D
dc.contributor.authorMoore, M
dc.contributor.authorKnox, J
dc.date.accessioned2016-10-12T13:04:00Z
dc.date.available2016-10-12T13:04:00Z
dc.date.issued2016-09-06
dc.identifier.citationFOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. 2016, 115 (6):649-54 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid27467054
dc.identifier.doi10.1038/bjc.2016.222
dc.identifier.urihttp://hdl.handle.net/10541/619940
dc.description.abstractFOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleFOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Torontoen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractFOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.


This item appears in the following Collection(s)

Show simple item record